Business Context and Reporting Period
This Form 8-K filing by Tempest Therapeutics, Inc. (TPST) reports corporate governance and executive compensation events occurring on July 1, 2021, and July 7, 2021. The company is a Delaware corporation listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and contractual agreements.
Material Changes
- Board Appointment: Christine Pellizzari was appointed as a Class II Director on July 1, 2021, with a term expiring in 2023. She has been appointed to the Audit Committee.
- Executive Employment Agreements: New employment agreements were executed on July 7, 2021, for the CEO, President, and Chief Medical Officer.
- Indemnification: All directors and executive officers entered into new indemnification agreements on July 1, 2021.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding business strategy or risks. It details specific compensation terms for key executives:
- Stephen Brady (CEO): Annual base salary of $475,283; target bonus of 40%; grant of 250,000 stock options. Severance includes 12 months' salary (or 18 months during change in control) plus bonus provisions and COBRA coverage.
- Thomas Dubensky, Ph.D. (President): Annual base salary of $476,283; target bonus of 40%; grant of 250,000 stock options. Severance includes 12 months' salary (or 18 months during change in control) plus bonus provisions and COBRA coverage.
- Samuel Whiting, M.D., Ph.D. (CMO): Annual base salary of $400,000; target bonus of 35%. Severance includes 9 months' salary (or 12 months during change in control) plus bonus provisions and COBRA coverage.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 500,000 new stock options granted to the CEO and President.
- Review the company's cash position to determine the ability to fund the new executive salaries and potential severance obligations.
- Confirm the qualifications and independence of the new director, Christine Pellizzari, particularly regarding her role on the Audit Committee.
- Examine the specific definitions of "cause," "good reason," and "change in control" within the attached employment agreements (Exhibits 10.2, 10.3, and 10.4).